HOME >> MEDICINE >> NEWS
Drug aimed at Huntington's eases chorea, the disease's hallmark feature

A drug widely available in Europe and Canada but not the United States dramatically eases one of the most disabling symptoms of Huntingtons disease, involuntary writhing movements known as chorea, according to a study in the Feb. 14 issue of the journal Neurology.

The medication, tetrabenazine, is currently being reviewed by the U.S. Food and Drug Administration. If approved, the medication would be the first authorized by the agency expressly for the treatment of Huntingtons disease, which affects about 30,000 people in the United States.

In a randomized, controlled study conducted in 84 patients at 16 sites around the nation, doctors found that the medication cut down involuntary movement on average by about 25 percent, with many patients experiencing a greater improvement. Overall, patients who received the medication were six times as likely to be considered by their doctors to have improved considerably, compared to participants who received a placebo.

Neuroleptic drugs like haloperidol (Haldol) are currently in widespread use in the United States to suppress chorea, but the effect of these drugs on chorea has never been studied in a systematic way, and they have a number of troublesome side effects, such as blunting of personality, loss of voluntary movement, and hindering balance. Our study showed that tetrabenazine, when appropriately dosed, can decrease chorea without causing those side effects, said Frederick J. Marshall, M.D., a neurologist at the University of Rochester Medical Center who led the study conducted by the Huntington Study Group. The study was funded by Prestwick Pharmaceuticals of Washington, D.C., the company that owns the rights to develop and sell the medication in the United States.

Tetrabenazine was originally developed in the 1950s to treat psychosis, but was quickly pushed aside by more effective medications. But doctors in the United Kingdom found it to be effective to treat the excessive involuntar
'"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
13-Feb-2006


Page: 1 2 3 4

Related medicine news :

1. Science of healthy foods subject of grant aimed at university students
2. Drug ads aimed at cancer patients difficult to read, make more appeals to effectiveness than safety
3. Cardiovascular flow disturbances study aimed at improving diagnosis and treatment
4. Endocrinologist-directed intervention aimed at primary care physicians improves diabetes care
5. New technology to speed up research into Huntingtons disease
6. Study identifies possible mechanism for brain damage in Huntingtons disease
7. Study identifies potential drug target for Huntingtons disease
8. Neural transplants provide persistent benefit in patients with Huntingtons disease
9. Rush designated Center of Excellence by Huntingtons Disease Society of America
10. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... ... January 18, 2017 , ... PrideStaff, ... Vice President of Franchise Development, Paula Turner Pizarro, was recently featured on Fox ... features the insights of top business leaders from across the globe, provides viewers ...
(Date:1/18/2017)... ... January 18, 2017 , ... Dr. Farhan Qureshi is ... and implants dentistry. His modern dental practice has two convenient office locations in Alexandria ... Top Rated Dentist for the Alexandria area. This award confirms the fact ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... of the revolutionary Active Brake Technology (ABT), an innovative braking system that allows ... Active Brake Technology addresses one of the biggest concerns of beginner and intermediate ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone ... choose the best drug option for each patient. Dentists have several general anesthesia alternatives ... outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting interview with medical expert ... that help everyone endure and pass through tough times, Dr. Bernie Siegel energizes ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)...  Tarix Orphan LLC today announced that the U.S. ... Disease (RPD) designation for the company,s drug candidate TXA127 ... a rare genetic skin disorder. There are currently no ... supportive care. "The RPD designation for TXA127 ... by the FDA in this indication," said Richard ...
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/18/2017)... Chinese Food and Drug Administration CSL CureVac ... Food and Drug Administration FORT Fresenius Pharmaceuticals ... Smith Klein GlaxoWellcome Global Influenza Programme ... Immune Targeting Systems Indian Association of Paediatrics ... & Johnson Krka Pharmaceuticals Medicago Medicare ...
Breaking Medicine Technology:
Cached News: